Marc Martinell Pedemonte
Fondateur chez Minoryx Therapeutics SL
Profil
Marc Martinell Pedemonte is the founder of Minoryx Therapeutics SL, where he currently holds the title of Chief Executive Officer & Director since 2011.
He is also the Director of l'Associació Catalana d'Empreses de Biotecnologia.
Previously, he worked as the Head-Biophysics at Crystax Pharmaceuticals SL.
Dr. Martinell Pedemonte obtained a doctorate degree from the University of Barcelona.
Postes actifs de Marc Martinell Pedemonte
| Sociétés | Poste | Début |
|---|---|---|
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Fondateur | 01/01/2011 |
l'Associació Catalana d'Empreses de Biotecnologia
 l'Associació Catalana d'Empreses de Biotecnologia Miscellaneous Commercial ServicesCommercial Services l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Anciens postes connus de Marc Martinell Pedemonte
| Sociétés | Poste | Fin |
|---|---|---|
Crystax Pharmaceuticals SL
 Crystax Pharmaceuticals SL Miscellaneous Commercial ServicesCommercial Services Crystax Pharmaceuticals is the first Spanish biotech dedicated to structure-based drug discovery. Located in Barcelona, Crystax was founded in 2002 by recognized scientists Miquel Coll and Juan Aymamí seeking to apply their structural biology knowledge and experience to the drug discovery process. Its mission is to find the best possible drug in the shortest time and with the highest rate of success. They aim to achieve this mission through its B2D2™ platform and the commitment of its team. Its biophysics based drug discovery platform B2D2™, covers the entire process from target cloning to lead optimization. Through structure determination of target proteins with the fragment hits, they obtain key structural information for the design of new compounds. They also use biophysical characterization to guide the follow-up of the initial hits. The result is an acceleration of the drug discovery process | Corporate Officer/Principal | 20/12/2011 |
Formation de Marc Martinell Pedemonte
| University of Barcelona | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Crystax Pharmaceuticals SL
Crystax Pharmaceuticals SL Miscellaneous Commercial ServicesCommercial Services Crystax Pharmaceuticals is the first Spanish biotech dedicated to structure-based drug discovery. Located in Barcelona, Crystax was founded in 2002 by recognized scientists Miquel Coll and Juan Aymamí seeking to apply their structural biology knowledge and experience to the drug discovery process. Its mission is to find the best possible drug in the shortest time and with the highest rate of success. They aim to achieve this mission through its B2D2™ platform and the commitment of its team. Its biophysics based drug discovery platform B2D2™, covers the entire process from target cloning to lead optimization. Through structure determination of target proteins with the fragment hits, they obtain key structural information for the design of new compounds. They also use biophysical characterization to guide the follow-up of the initial hits. The result is an acceleration of the drug discovery process | Commercial Services |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Health Technology |
l'Associació Catalana d'Empreses de Biotecnologia
l'Associació Catalana d'Empreses de Biotecnologia Miscellaneous Commercial ServicesCommercial Services l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain. | Commercial Services |